+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID04519151

Phase 2 Study of Pembrolizumab and Lenvatinib Combination Therapy for Women with Platinum-Sensitive Recurrent Ovarian Cancer

Led by Sheba Medical Center · Updated on 2023-06-08

24

Participants Needed

1

Research Sites

313 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of pembrolizumab and lenvatinib for treating platinum-sensitive recurrent ovarian cancer in this phase 2, open-label, single-arm study. The study focuses on adult female patients with confirmed epithelial ovarian cancer, excluding low-grade tumors and mucinous types, who have experienced disease recurrence after surgery and prior platinum-based chemotherapy. The goal is to assess the effect of this combination therapy on disease progression and overall patient outcomes. Participants will receive oral lenvatinib 20 mg daily alongside intravenous pembrolizumab 200 mg every three weeks for up to 35 treatment cycles or until disease progression or unacceptable toxicity. If participants complete pembrolizumab treatment or achieve complete response, they may continue lenvatinib alone or reinitiate pembrolizumab with or without lenvatinib for up to one year upon disease progression. The treatment is carefully monitored with dose adjustments allowed for lenvatinib in response to side effects. During the study, participants will undergo regular imaging with CT or MRI scans every nine weeks to track disease status. Safety is evaluated through adverse event monitoring using standardized criteria, along with laboratory tests and blood pressure checks. Quality of life assessments will be conducted using validated questionnaires. Additionally, biological samples including tumor biopsies, blood, stool, and vaginal swabs will be collected to study biomarkers and treatment response. The study lasts up to approximately 27 months, including follow-up and potential extended treatment phases.

CONDITIONS

Brief Title

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Research Team

R

Ronnie Shapira, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here